Become a member

X
Quick Registration


Full Registration Benefits -

Free Homepages for Doctors

Free Homepages for Hospitals

Free Homepages for Medical Conference

Free Homepages for NGO's

Personal Health Record Creation

Access to all Medical Slides

Access to all Jobs & Products Sale

Custom Search
Explore Medindia
Home » Cancer News

Erlotinib Dose-Adjusted for Smoking Status Efficient As Initial Treatment for Head & Neck Cancer

by Nancy Needhima on  January 30, 2012 at 10:00 PM Cancer News
  •   Print
  •   Share
  •   Comments
  •  Text 
 The anti-cancer drug erlotinib is effective in Head and neck cancers since the cancers respond well to the drug when it is administered before surgery and a stronger dose is given to patients who smoke, states study presented at the Multidisciplinary Head and Neck Cancer Symposium. It is sponsored by AHNS, ASCO, ASTRO and SNM.Erlotinib is an oral anti-cancer drug that can slow a tumor's growth and spread by inhibiting specific growth receptors on the surface of the cancer cells. Early detection of a patient's response to EGFR inhibitors, such as erlotinib, is critical to personalizing head and neck cancer treatments. In a first of its kind study in patients with head and neck cancer, researchers sought to determine how well tumors unaffected by other therapies respond to erlotinib, when the drug dose was adjusted according to the patient's smoking status. It has been recently shown that smokers metabolize the drug faster than nonsmokers.Nonsmokers received 150 mg per day and smokers received 300 mg per day for at least 14 days before surgery. A FDG-PET scan and neck CT was performed before treatment and at the end of erlotinib administration. In addition, an early FDG-PET was performed after four to six days of treatment. The results showed that erlotinib is effective as a first line of therapy when the dose is adjusted per smoking status, even when used for a limited duration. Both smokers and nonsmokers tolerated the dose of erlotinib and neither experienced serious adverse effects. The study also showed that the FDG-PET scan taken early can show changes in the standard uptake value and predict a patient's response to erlotinib."We hope our results will motivate clinicians to consider and investigate further the use of erlotinib in patients with head and neck cancer and adjust the dose for smoking status," Mercedes Porosnicu, MD, lead author of the study and an assistant professor of internal medicine at Wake Forest Baptist Medical Center in Winston Salem, N.C., said. "We also hope that our study will help better select the patients expected to respond to erlotinib."

Source-Eurekalert

 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
More News on: Health Hazards of Smoking, Smoking And Cancer, Smoking And Tobacco, Smoking Risk, Diet Lifestyle and Heart Disease, Bubbles and Brews - Alcohol Facts, Smoking, Cigarette Smoking - A Silent Killer, Chronic Obstructive Pulmonary Disease, Leriche Syndrome
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions 		  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

Total Members - 62122
Support Groups - 445
Login  Join Now
Medwonders Health Network
  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
Quiz on Cancer
Looking for information on cancer? Go through medindia's Cancer quiz.
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Smoking
Complete Medindia Resources
News Categories:  
Kidney Health Center

Cancer Related News
» Cardio-Pulmonary Function can be a Strong Indicator for Survival Chances of Breast Cancer Patients » Post Surgery Will the Tumour Return? New Breast Cancer Test to Predict Exactly
» Scientists Develop Compound That Triggers Cancer Cell Death » Iraqi National Hopes to Find Affordable Treatment for His Cancer in India
» New Technique can Help Doctors Detect Pancreatic Cancer » Colorectal Cancer Risk Factors Probed
» Breast MRI 'Better Than Clinical Approach for Predicting Chemotherapy's Efficiency' » No Need for PSA-Based Screening for Prostate Cancer: Task Force
Read More >>

Consumers

Online Consults Child Health Teen Health Men's Health Women's Health Senior Health Sexual Health Mental Health Dental Health Kidney Health
Diabetes Obesity Vision Care Diet & Nutrition Know Your Body Amazing Body Facts Health Facts Conditions by Specialties Disease FAQs Medical Humour

Medical Professionals

Health Calculators Health Videos Animation Slides Medical Aphorism Medical Conferences Jobs Journals Web Journals Open Access E-articles
Distance education Doctors Homepage Hospitals Homepage Personalize Info Matrimonial Print Oath Alumni Medical Humour Buy Books

Medical Students

Admissions Medical Colleges Medical Electives Medical Aphorism Post Grad Courses Indian Universities USMLE Centers CGFNS Centers
FRCS in UK PLAB USMLE CGFNS Alumni MCQ Bank Medical Humour Buy Books

Directories

Doctors Hospitals International Hospitals Chemists Surgical Suppliers NGOs Pharmaceuticals Medical Colleges
About us Advertise Affiliate Program Career Contact Us Content Syndication Partnership Inquires Portfolio Press Request to Use Medindia Content Sitemap
Disclaimer - The contents of this site are for informational purposes only. Always seek the advice of a qualified physician for any doubts.
Advertise with us Medindia Copyright Privacy Policy Terms of Use
© All Rights Reserved 1997 - 2012